1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sutro Biopharma, Inc.

Sutro Biopharma, Inc.

STRO
Sutro Biopharma, Inc.US flagNASDAQ Global Market
27.18
USD
+2.75
- -
263.03MMarket Cap

Total Valuation

Sutro Biopharma, Inc. carries a market capitalization of 263.03M, placing it among publicly traded companies globally. Its enterprise value stands at 60.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap263.03M
Enterprise Value60.40M

Share Statistics

Sutro Biopharma, Inc. currently has 16.57M shares outstanding.

Shares Outstanding16.57M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.50, and the price-to-book ratio stands at -0.25.

PE RatioN/A
PS Ratio2.50
PB Ratio-0.25
P/TBV Ratio-3.73
P/FCF Ratio-1.65
P/OCF Ratio-1.64

Enterprise Valuation

EV / Sales0.61
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Sutro Biopharma, Inc. maintains a current ratio of 3.12, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -20.38, indicating conservative leverage, while an interest coverage ratio of -1.92 demonstrates limited ability to service its debt obligations.

Current Ratio3.12
Quick Ratio3.04
Debt / Equity-20.38
Debt / EBITDA-0.17
Interest Coverage-1.92

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-54.53
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory TurnoverN/A

Taxes

Income Tax-115,000.00
Effective Tax RateN/A

Stock Price Statistics

Sutro Biopharma, Inc.'s stock has gained approximately 197.69989% over the past 52 weeks. The 50-day moving average sits at 31.03, while the 200-day moving average is 16.92.

Beta (5Y)N/A
52-Week Price Change197.69989%
50-Day Moving Average31.03
200-Day Moving Average16.92
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Sutro Biopharma, Inc. generated 99.61M in revenue and converted that into -153.60M in net income, yielding earnings per share of -15.35. EBITDA reached -80.39M, while operating income came in at -87.09M.

Revenue99.61M
Gross ProfitN/A
Operating Income-87.09M
Pretax Income-153.72M
Net Income-153.60M
EBITDA-80.39M
EBIT-87.09M
Earnings Per Share (EPS)-15.35

Balance Sheet

Sutro Biopharma, Inc. holds 202.56M in cash and equivalents against 13.63M in total debt, resulting in a net debt position of -73.68M. Total book value stands at -1.02B, with working capital of 150.16M providing operational flexibility.

Cash & Cash Equivalents202.56M
Total Debt13.63M
Net Debt-73.68M
Equity (Book Value)-1.02B
Book Value Per Share-101.55
Working Capital150.16M

Cash Flow

Sutro Biopharma, Inc. produced -151.61M in operating cash flow over the past twelve months. After subtracting -532,000.00 in capital expenditures, free cash flow totaled -152.14M - equivalent to -15.20 per share.

Operating Cash Flow-151.61M
Capital Expenditures-532,000.00
Free Cash Flow-152.14M
FCF Per Share-15.20

Margins

Sutro Biopharma, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -87.44 and net profit margin of -154.21 provide insight into operational efficiency.

Gross Margin100.00
Operating Margin-87.44
Pretax Margin-154.32
Profit Margin-154.21
EBITDA Margin-80.71

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-41.33
FCF Yield-60.59

Stock Splits

Sutro Biopharma, Inc.'s most recent stock split took place on December 3, 2025 with a 10:1 split ratio.

Last Split Date12/3/2025
Split Ratio10:1

Scores

Sutro Biopharma, Inc. posts an Altman Z-Score of -5.43, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-5.43